Screener
Travere Therapeutics, Inc. TVTX Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The source filing: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:45 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001438533-26-000042
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Interest expense | (2,300) | (2,857) |
| Other (expense) income, net | (91) | 549 |
| Total other income, net | 193 | 1,487 |
| Loss from continuing operations before income tax | (36,722) | (41,187) |
| Income tax benefit (provision) on continuing operations | 120 | (39) |
| Loss from continuing operations, net of tax | (36,602) | (41,226) |
| Loss from discontinued operations, net of tax | (500) | — |
| Net loss | $(37,102) | $(41,226) |
Item 1. Financial Statements
FAQ
- What is Travere Therapeutics, Inc.'s pre-tax income?
- Travere Therapeutics, Inc. (TVTX) reported pre-tax income of -$36.72M in Q1 2026.
- How has Travere Therapeutics, Inc.'s pre-tax income changed year-over-year?
- Travere Therapeutics, Inc.'s pre-tax income increased by 10.8% year-over-year, from -$41.19M to -$36.72M.
- What is the long-term trend for Travere Therapeutics, Inc.'s pre-tax income?
- Over 4 years (2021 to 2025), Travere Therapeutics, Inc.'s pre-tax income has grown at a -31.0% compound annual growth rate (CAGR), from -$216.88M to -$49.27M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.
Ask your AI about Travere Therapeutics, Inc.'s pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude